[1]赵 寻,张晓磊,朱家旺.重组人脑利钠肽联合硝普钠对急性心衰患者疗效、安全性及预后的影响[J].医学信息,2021,34(09):153-155.[doi:10.3969/j.issn.1006-1959.2021.09.041]
　ZHAO Xun,ZHANG Xiao-lei,ZHU Jia-wang.Effect of Recombinant Human Brain Natriuretic Peptide Combined with Sodium Nitroprusside on the Curative Effect and Prognosis of Patients with Acute Heart Failure[J].Medical Information,2021,34(09):153-155.[doi:10.3969/j.issn.1006-1959.2021.09.041]
点击复制

重组人脑利钠肽联合硝普钠对急性心衰患者疗效、安全性及预后的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年09期
页码:
153-155
栏目:
药物与临床
出版日期:
2021-05-01

文章信息/Info

Title:
Effect of Recombinant Human Brain Natriuretic Peptide Combined with Sodium Nitroprusside on the Curative Effect and Prognosis of Patients with Acute Heart Failure
文章编号:
1006-1959（2021）09-0153-03
作者:
赵 寻; 张晓磊; 朱家旺
（天津中医药大学第二附属医院急症科，天津 300150）
Author(s):
ZHAO Xun; ZHANG Xiao-lei; ZHU Jia-wang
(Emergency Department of the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150,China)
关键词:
重组人脑利钠肽; 硝普钠; 急性心衰
Keywords:
Recombinant human brain natriuretic peptide; Sodium nitroprusside; Acute heart failure
分类号:
R541.6
DOI:
10.3969/j.issn.1006-1959.2021.09.041
文献标志码:
A
摘要:
目的 观察重组人脑利钠肽联合硝普钠治疗急性心衰的临床疗效、安全性以及预后。方法 选取2019年10月~2020年10月在我院诊治的116例急性心衰患者为研究对象，采用随机数字表法分为对照组和观察组，各58例。对照组采用硝普钠治疗，观察组在对照组基础上联合重组人脑利钠肽治疗，比较两组临床治疗总有效率、心功能指标、血清NT-proBNP、hs-CRP、cTnI水平、临床不良反应发生率以及随访1年不良心血管事件发生率。结果 观察组治疗总有效率为96.55%，高于对照组的84.48%，差异有统计学意义（P＜0.05）；治疗后两组心率、左心房内径、左心室内径均低于治疗前，LVEF均高于治疗前，且观察组心率、左心房内径、左心室内径均低于对照组，LVEF均高于对照组，差异有统计学意义（P＜0.05）；治疗后两组血清NT-proBNP、hs-CRP、cTnI均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；观察组不良反应发生率为6.89%，与对照组的5.17%比较，差异无统计学意义（P＞0.05）；随访1年，观察组不良心血管事件发生率为10.34%，低于对照组的22.41%，差异有统计学意义（P＜0.05）。结论 重组人脑利钠肽联合硝普钠治疗急性心衰，可提高治疗总有效率，促进心率恢复，降低NT-proBNP、hs-CRP、cTnI水平，改善心脏功能，降低远期不良心血管事件，且不会增加临床不良反应。
Abstract:
Objective To observe the clinical efficacy, safety and prognosis of recombinant human brain natriuretic peptide combined with sodium nitroprusside in the treatment of acute heart failure.Methods A total of 116 patients with acute heart failure who were diagnosed and treated in our hospital from October 2019 to October 2020 were selected as the research objects. They were divided into a control group and an observation group using a random number table method, with 58 cases in each group.The control group was treated with sodium nitroprusside, and the observation group was treated with recombinant human brain natriuretic peptide on the basis of the control group.The total effective rate of clinical treatment, cardiac function indexes, serum NT-proBNP, hs-CRP, cTnI levels, the incidence of clinical adverse reactions and the incidence of adverse cardiovascular events were compared between the two groups of clinical treatment.Results The total effective rate of treatment in the observation group was 96.55%, which was higher than 84.48% in the control group,the difference was statistically significant (P＜0.05);After treatment, the heart rate, left atrium inner diameter, and left ventricular diameter of the two groups were lower than before treatment, and LVEF was higher than before treatment, and the heart rate, left atrium inner diameter, and left ventricular diameter of the observation group were lower than those of the control group, and the LVEF was higher than that of the control group,the difference was statistically significant (P＜0.05);After treatment, the serum NT-proBNP, hs-CRP and cTnI of the two groups were lower than before treatment, and the observation group was lower than the control group, the difference was statistically significant (P＜0.05);The incidence of adverse reactions in the observation group was 6.89%, compared with 5.17% in the control group, the difference was not statistically significant (P＞0.05);After 1 year of follow-up, the incidence of adverse cardiovascular events in the observation group was 10.34%, which was lower than 22.41% in the control group,the difference was statistically significant (P＜0.05).Conclusion Recombinant human brain natriuretic peptide combined with sodium nitroprusside in the treatment of acute heart failure can increase the total effective rate of treatment, promote heart rate recovery, reduce NT-proBNP, hs-CRP, cTnI levels, and improve cardiac function.Reduce long-term adverse cardiovascular events without increasing clinical adverse reactions.

参考文献/References:

[1]何瑞玲.米力农治疗顽固性心力衰竭的临床研究[J].中国医学创新,2015,12(1):71-73. [2]杨涛,杨露,海峰,等.硝普钠与多巴胺联用治疗难治性心衰患者的临床疗效[J].西部医学,2017,29(12):1676. [3]钱招昕,孙明,陈玉梅.心衰患者硝普钠治疗前后心脏内径与射血分数变化的研究[J].湖南医科大学学报,2017,35(1):44-46. [4]李娜,盛柯杰,白梦蝶,等.重组人脑利钠肽治疗急性心力衰竭的疗效及对血清炎性因子的影响[J].海军医学杂志,2019(4):333-335. [5]翟莉,李勤明,胡艳丽,等.左西孟旦在急性心衰患者中的临床应用[J].中国分子心脏病学杂志,2017,18(4):2156-2158. [6]王智.硝普钠联合多巴胺对急性心力衰竭患者CRP、BNP及LVEF的影响[J].心脑血管病防治,2017,17(5):391-392. [7]郑振达,成彩联,曲彩虹,等.重组人脑利钠肽联合左西孟旦治疗急性心肌梗死合并心力衰竭的疗效观察[J].中华老年医学杂志,2015,34(11):1231-1234. [8]薛慧.硝普钠联合多巴胺对心力衰竭血流动力学和肾功能的影响分析[J].长春大学学报,2017,27(12):62. [9]史濛,彭桂香,王颜,等.硝普钠与多巴胺持续静脉泵入联合个性化护理治疗充血性心力衰竭55例临床评价[J].中国药业,2017,26(24):30. [10]Eduardo RA,Gary EW,John SF,et al.Reducing cardiac filling pressure lowers norepinephine spill over in patients with chronic heart failure[J].Circulation,2017,35(1):44-46. [11]李玉兰.硝普钠治疗急性心衰伴射血分数保留患者对心功能影响观察[J].中国民康医学,2017,29(1):5-7,51. [12]宋艳.硝普钠联合多巴酚丁胺治疗急性心力衰竭患者临床效果及对肾功能的影响[J].临床合理用药杂志,2017,10(23):26. [13]郭牧,张云强,梁海清,等.左西孟旦联合重组人脑利钠肽治疗急性心力衰竭的临床研究[J].临床心血管病杂志,2014,30(4):286-290. [14]傅涛,荆忱,徐佳,等.冻干重组人脑利钠肽治疗缺血性心肌病室性心律失常和急性心力衰竭的疗效和安全性评价[J].北京医学,2017,39(6):607-610,614. [15]孙颖,郝艳丽,李延辉,等.重组人脑利钠肽辅助治疗老年心力衰竭患者的疗效及其对心功能、炎性指标的影响[J].疑难病杂志,2017,16(1):10-13.

相似文献/References:

[1]程 林.重组人脑利钠肽用于重症急性心肌炎伴 心力衰竭患者治疗的临床研究[J].医学信息,2018,31(08):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
　CHENG Lin.Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure[J].Medical Information,2018,31(09):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
[2]苏长阳,帅东东,王 磊,等.硝普钠联合多巴胺治疗心肌梗死后左心衰竭的疗效[J].医学信息,2021,34(03):157.[doi:10.3969/j.issn.1006-1959.2021.03.044]
　SU Chang-yang,SHUAI Dong-dong,WANG Lei,et al.Efficacy of Sodium Nitroprusside Combined with Dopamine in the Treatment of Left Heart Failure After Myocardial Infarction[J].Medical Information,2021,34(09):157.[doi:10.3969/j.issn.1006-1959.2021.03.044]
[3]苏比努尔·依力哈尔,方志敏,张立秋,等.重组人脑利钠肽对急性前壁心肌梗死介入术后心肌再灌注损伤的影响[J].医学信息,2023,36(08):189.[doi:10.3969/j.issn.1006-1959.2023.08.042]
　Subinuer·Yilihaer,FANG Zhi-min,ZHANG Li-qiu,et al.Effect of Recombinant Human Brain Natriuretic Peptide on Myocardial Reperfusion Injury After Percutaneous Coronary Intervention in Acute Anterior Myocardial Infarction[J].Medical Information,2023,36(09):189.[doi:10.3969/j.issn.1006-1959.2023.08.042]
[4]郑国盛.多巴胺联合硝普钠治疗急性心力衰竭伴低血压的临床效果及对心功能和预后的影响[J].医学信息,2023,36(14):137.[doi:10.3969/j.issn.1006-1959.2023.14.028]
　ZHENG Guo-sheng.Clinical Effect of Dopamine Combined with Sodium Nitroprusside in the Treatment of Acute Heart Failure with Hypotension and its Effect on Cardiac Function and Prognosis[J].Medical Information,2023,36(09):137.[doi:10.3969/j.issn.1006-1959.2023.14.028]

更新日期/Last Update: 1900-01-01